Agile Therapeutics (AGRX) Provides Regulatory Update and Reiterates Cash Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Stocks fall as higher oil prices, Treasury yields weigh
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
Agile Therapeutics, Inc. Provides Regulatory Update and Reiterates Cash Guidance
January 10, 2019 4:15 PM ESTDiscussions with FDA on Design of Comparative Wear Study of Twirla® and Xulane® CompletedÂ
Cash Expected to Enable Company to Fund Operations into Second Quarter of 2019
PRINCETON, N.J., Jan. 10, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (Nasdaq: AGRX), a womens healthcare company, today announced that on January 9, 2019 it received final meeting minutes from its December 11, 2018 meeting with the U.S. Food and Drug Administrations (FDA) Division of Bone, Reproductive, and Urologic Products (DBRUP). The Company met with DBRUP to discuss the design of a comparative... More
